Completed
Ofatumumab Plus Bendamustine in Frontline and Relapsed Chronic Lymphocytic Leukaemia (CLL)
NCT01520922
- Conditions
- Chronic Disease, Chronic Lymphocytic Leukemia (CLL), Disease Attributes, +17 more
- Locations
-
- Novartis Investigative Site Tuscon, Arizona, United States
- Novartis Investigative Site Aurora, Colorado, United States
- Novartis Investigative Site Fort Myers, Florida, United States
- Novartis Investigative Site St. Petersburg, Florida, United States